Premium
Differentiating keratoacanthoma from squamous cell carcinoma—In quest of the holy grail
Author(s) -
Nagarajan Priyadharsini
Publication year - 2020
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13640
Subject(s) - dermatopathology , keratoacanthoma , pathology , basal cell , interleukin 3 receptor , holy grail , immunohistochemistry , biomarker , medicine , plasmacytoid dendritic cell , immune system , biology , immunology , dendritic cell , myeloid , biochemistry , world wide web , computer science
To distinguish keratoacanthomas from squamous cell carcinomas remains a diagnostic challenge in dermatopathology. Several immunohistochemical and cytogenetic markers have been evaluated; however, so far there has been no unequivocal evidence supporting practical application of any of these markers. Recent studies have evaluated the composition of tumor‐associated immune infiltrate, in particular the number and distribution of CD123‐positive plasmacytoid dendritic cells in making this distinction; but these cells also do not appear to be a consistent biomarker in distinguishing keratoacanthoma from squamous cell carcinoma.